Oculus Innovative Sciences Inc.


Ticker Symbol: OCLS

Oculus Innovative Sciences Inc. (NASDAQ: OCLS) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care.

Company Overview

Oculus Innovative Sciences Inc. (NASDAQ: OCLS) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care.

The company's Microcyn technology is based on electrically charged oxychloridne small molecules designed to target a wide range of pathogens that cause disease. Its products have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses.

So far, the company has obtained eleven 501(k) clearances from the U.S. FDA to sell its products as medical devices and has launched at least one new dermatology product per quarter in FY 2016.

Investment Highlights

  • Attractive Market. Oculus Innovative Sciences targets large addressable markets with favorable product pricing and elasticity with a technology that has proven effectiveness. Dermatologists are high prescribers and early adopters and the concentrated market can be covered by a relatively small sales force of ~35 sales representatives.
  • Strong Growth. The company has double-digit product revenue growth driven by a newly established U.S. direct sales force and plans to launch at least one new dermatology product per quarter in 2016. In addition, the company has a $16 million annualized revenue run rate with $6.1 million in cash and no debt.
  • Effective Technology. The company's Microcyn technology has been shown to be both very safe and highly effective in over 35 clinical trials. Over five million patients have used the technology to reduce itching, scarring, inflammation, skin infections, and pain, as well as to improve skin healing.
  • Experienced Leadership. The company is led by a strong management team and Board of Directors. CEO Jim Schutz has run previous companies that have been acquired by Abbott and Volcano Corporation, while CFO Robert Miller has over 12 years of experience in CFO roles for companies worth up to $650 million.

Download the Complete OCLS Company Analysis

Report

Download a free SECFilings Company Analysis on Oculus Innovative Sciences Inc. that covers:

  • Recent Developments - A review of recent developments and their impact on the company's bottom line.
  • Financial Analysis - A detailed review of the company's income statement, balance sheet, and cash flow statement.
  • Peer Comparison - A detailed list of industry peers and the company's relative valuation, growth rates, and much more.

Enter your e-mail below to receive the free analysis:

I also want to receive reports on similar opportunities in the space from time to time. We promise not to send spam.